A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Conditions

• Plaque Psoriasis

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• JNJ-77242113 — DRUG
  JNJ-77242113 will be administered orally.
• JNJ-77242113 Matching Placebo — DRUG
  JNJ-77242113 matching placebo will be administered orally.
• Deucravacitinib — DRUG
  Deucravacitinib will be administered orally.
• Deucravacitinib Matching Placebo — DRUG
  Deucravacitinib matching placebo will be administered orally.

Study Details

The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.

Key Dates

Start date

Feb 1, 2024

Status verified

Mar 2026

Primary completion

Sep 17, 2024

Completion

Jun 1, 2027

Study Design

Enrollment

774 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: JNJ-77242113
  Participants will receive JNJ-77242113 from Week 0 through Week 156 and deucravacitinib matching placebo from Week 0 through Week 24.
• Placebo Comparator: Placebo
  Participants will receive matching placebo for JNJ-77242113 from Week 0 through Week 16, matching placebo for deucravacitinib from Week 0 through Week 24 and JNJ-77242113 from Week 16 through Week 156.
• Active Comparator: Deucravacitinib
  Participants will receive deucravacitinib from Week 0 through Week 24 and matching placebo for JNJ-77242113 from Week 0 through Week 24 and JNJ-77242113 from Week 24 through Week 156.

Primary Outcome Measure

JNJ-77242113 and Placebo Group: Percentage of Participants Achieving an Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater Than or Equal to (>=) 2-Grade Improvement From Baseline to Week 16 [ Time Frame: Baseline and Week 16 ]

Locations (50)

Find similar trials in Phoenix, AZ

Related Studies

• Triamcinolone With Vitamin D Synergistic Efficacy in Psoriasis
  EARLY_PHASE1 · Recruiting · Wright State University · Fairborn, Ohio
• Understanding Participation Habits Among Plaque Psoriasis Patients
  Not Yet Recruiting · Power Life Sciences Inc. · San Francisco, California
• A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
  PHASE3 · Recruiting · Bristol-Myers Squibb · Birmingham, Alabama
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in Healthy Participants and Participants With Plaque Psoriasis
  PHASE1 · Recruiting · Ascletis Pharma (China) Co., Limited · Miami, Florida